Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 1, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital.
| Metric | Value as of May 31, 2017 |
|---|---|
| Total Issued Ordinary Shares | 5,371,061,656 |
| Share Class | Ordinary Shares of 25 pence each |
| Treasury Shares | 453,205,950 |
| Total Voting Rights | 4,917,855,706 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely reports the static capital structure as of May 31, 2017.
Guidance, Outlook, and Risks
The document contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholders to calculate notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Total voting rights are 4,917,855,706, calculated by subtracting treasury shares from total issued shares.
- Treasury shares held by the Company total 453,205,950.
- The reported share capital figure is effective as of May 31, 2017.
- This filing does not contain financial results; investors should refer to Form 20-F for financial data.